Amwill Health Care Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 1,026,000 (19%) | — | ₹1,139 Cr |
| NII (HNI) | — | 2,053,200 (38%) | — | ₹2,279 Cr |
| Retail | — | 2,053,200 (38%) | — | ₹2,279 Cr |
| Market Maker | — | 271,200 (5%) | — | ₹30 Cr |
| Σ Total | — | 5,403,600 (100%) | — | ₹59,980 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 1,200 | ₹133,200 |
| Retail (Max) | 13 | 15,600 | ₹1,731,600 |
| S-HNI (Min) | 14 | 16,800 | ₹1,864,800 |
| B-HNI (Min) | 67 | 80,400 | ₹8,924,400 |
Financial Statements Amount in ₹ Crores
| Metric | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Revenue | 23 | 44 | 30 |
| Profit After Tax | 7 | 13 | 3 |
| Net Worth | 24 | 17 | 5 |
| Total Assets | 29 | 19 | 12 |
| Reserves & Surplus | 8 | 17 | 5 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- Funding of working capital requirements of the Company –
- Marketing and brand-building activities –
- General corporate purposes –
Company Overview
Incorporated in August 2017, Amwill Health Care Limited is a derma-cosmetic development firm that collaborates with contract manufacturers, distributors, and third-party product development agencies. This collaboration has enhanced the company's manufacturing, packaging, and distribution capabilities.
The product portfolio of the Company is divided into two categories, namely,
- Development of generic dermatological solutions and
- Formulating targeted solutions for dermatological issues.
The company markets its products in Karnataka, Andhra Pradesh, and Telangana, focusing on strengthening its presence before entering new markets to build a customer base.
The company develops products for dermatological disorders, including acne, fungal infections, anti-aging, histaminic, periorbital hyperpigmentation, scabies, perspiration, trichology, and vitiligo.
As of September 30, 2024, the company has 84 employees on payroll.
Competitive Strength
- Extensive product portfolio supported by product formulation capabilities
- Provision of high-quality product development through tie-ups with contract manufacturers and prototype developers
- Well-experienced management team with proven project management and implementation skills
- Asset-light business model.